VKTX240927C65000
- 0.70
- 0.000.00%
Viking Therapeutics Newsroom
Next Frontier in Anti-obesity Landscape: Oral GLP-1s With Potential OTC Switch
Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Viking Therapeutics Unusual Options Activity For September 24
Weight loss candidate drug nimacimab safety approved. Skye (SKYE.US) stock price soared 11%.
Skye Bioscience's stock price soared 11%, benefiting from the safety differences between its weight loss candidate drug nimacimab and novo-nordisk a/s's monlunabant.
10 Health Care Stocks With Whale Alerts In Today's Session
Skye Stock Rallies 22% Following Weight-loss Drug Update
Viking Therapeutics, Inc. (VKTX): Biotech Breakthrough or Short Sellers' Target?
Viking Therapeutics(VKTX.US) Officer Sells US$15.31 Million in Common Stock
$Viking Therapeutics(VKTX.US)$ Officer Lian Brian sold 216.13K shares of common stock on Sep 20, 2024 at an average price of $70.8303 for a total value of $15.31 million.Source: Announcement What is
Viking Therapeutics CEO Sells Over $15m in Company Stock
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
Form 144 | Viking Therapeutics(VKTX.US) Officer Proposes to Sell 3.98 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 20, $Viking Therapeutics(VKTX.US)$ Officer Lian Brian intends to sell 216.13K shares of its common stock on Sep 20, with a total market value of approximately $3.98
Viking, Structure, Terns Benefitting From Disappointing Novo Nordisk Weight Loss Data
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill -- WSJ
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
New Dimensions in Pavement Markings Successfully Acquired by Strategic Buyer
What the Options Market Tells Us About Viking Therapeutics
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95
Stifel analyst Annabel Samimy maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 45.2%
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Viking Therapeutics(VKTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.4% and a total average return of 24.3%